RAC - Charts & Price Action, page-25885

STATEMENT: "Probably more important right now for investors is what is RC220 worth just as an anticancer drug"

QUESTIONS: "Where does the anti cancer properties of rc220 fit in the current scope of clinical management? Surely not as a traditional chemo drug? So how does an investor evaluate what potential rc220 has when we don't know where it fits in current guidelines".

Here is how I would begin to look at the anti cancer drug aspect of RC220, and go forward from there; [This is SPECULATIVE]!

The emergence of RC220 means that Bisantrene is now safe for use in all of the cancer indications that it previously proved to be effective in: thats where the old data from 1500 patients comes in. Obviously, some new treatments have come in so there will be some indications where it may have fallen down the packing order.

What that means is that, RC220 is quite possibly already in a state where RAC could move it towards an FDA approval based on old third party data, which is allowed via 505(b)2 regulatory pathway. That pathway will almost certainly require a bridging trial - a P3, in the US (to confirm it still works in humans and a few things). Surely, someone will pay to fund that last step - I believe!

Anyhow, a bridging trial will succeed, unless some issue happens, such as bad batches, come to play. RAC could just select only the indications where RC110 did best, and prove that Bisantrene still works today as it did before.

So, those who know how to value assets - that to me is where it is: a short few years from filing for FDA approval. As for a place on the Clinical Guidelines - that will be after a successful P3 trial - the shareprice will be so high that many here will have jumped ship. For those who chose to stay - BP might deal with that.

Frankly, when I am here, I just wear my biotech investor hat, and I do not worry myself about clinical guidelines!

----
Speculation only!